Role of Anti-VEGF (Bevacizumab) in Management of Neovascular Glaucoma: A Review

Alharfy, Abdulrahman Arshed N. and Albalawi, Marwan Saleh D. and Alzahrani, Abdulmajeed Mousa and Alsubaie, Ruby Naif M. and Albalawi, Amani Ahmad S. and Alkaabneh, Waad Ali and Altidlawi, Abdullah Ibrahim and Alharbi, Amal Nafea J. and Almutairi, Afnan Mohammed H. and Alotabi, Rola Ali S. (2021) Role of Anti-VEGF (Bevacizumab) in Management of Neovascular Glaucoma: A Review. Journal of Pharmaceutical Research International, 33 (40A). pp. 215-221. ISSN 2456-9119

[thumbnail of 3049-Article Text-4773-2-10-20221006.pdf]

Text
3049-Article Text-4773-2-10-20221006.pdf - Published Version
Download (183kB)

Official URL: https://doi.org/10.9734/jpri/2021/v33i40A32237

Abstract

Neovascular glaucoma (NVG) is an aggressive type of glaucoma, which often results in poor visual outcomes. Antivascular endothelial growth factor is frequently used for various conditions in which VEGF release is induced in response to retinal ischemia. Bevacizumab is a humanized anti-VEGF monoclonal IgG1 antibody. The potential of antivascular endothelial growth factor (anti-VEGF) agents to modify the disease course of neovascular glaucoma (NVG) was recognized shortly after their use in the treatment of age-related macular degeneration was reported. These medications were noted to induce rapid regression of the anterior segment neovascularization that characterizes NVG. Several studies as well as extensive clinical experience have demonstrated a rapid regression of anterior segment neovascularization following the injection of anti-VEGF agents. This review aims to summarize current evidences regarding effectiveness of Bevacizumab in management of neovascular glaucoma.

Item Type:	Article
Subjects:	European Repository > Medical Science
Depositing User:	Managing Editor
Date Deposited:	19 Apr 2023 04:24
Last Modified:	09 Feb 2024 03:49
URI:	http://go7publish.com/id/eprint/1636

Actions (login required)

: View Item